Redmile Group is an investment management firm that primarily focuses on investments in U.S. and non-U.S. healthcare companies, particularly in the biotechnology sector. The firm employs various strategies, including hedge fund and private equity approaches, often with a concentrated focus on clinical-stage biotechnology companies.
Portfolio
14
Fund Size
$4.8B
Top Stage
Series B
Last 12 Mo
2
Stage Distribution
Portfolio
14 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Bambusa Therapeutics | Series A | — | Nov 2025 |
| One Biosciences | Series A | $15M | Jul 2025 |
| Bambusa Therapeutics | Series A | — | Feb 2025 |
| Mnemo Therapeutics | Series A | $90M | Jun 2021 |
| AbSci | Series D | $125M | Mar 2021 |
| Amunix Pharmaceuticals, Inc. | Series B | $117M | Mar 2021 |
| Genalyte | Series C | $50M | Jan 2021 |
| ElevateBio | Series B | $170M | Mar 2020 |
| Augmedix | Series B | $19M | Oct 2019 |
| IGM Biosciences | Series C | $102M | Jul 2019 |
| Saluda Medical | Growth | $75M | Jun 2019 |
| Akero Therapeutics | Series B | $70M | Dec 2018 |
| Aprea Therapeutics | Series C | $50M | Nov 2018 |
| Virta | Series B | $37M | Mar 2017 |
Top Co-Investors
Janus Henderson Investors5 shared
Invus4 shared
Casdin Capital3 shared
Rock Springs Capital2 shared
Versant Ventures2 shared
Sofinnova Partners2 shared
ArrowMark Partners2 shared
RA Capital Management2 shared
Venrock2 shared
Khosla Ventures1 shared
Cormorant Asset Management1 shared
Apple Tree Partners1 shared
Atlas Venture1 shared
venBio1 shared
McKesson Ventures1 shared
DCM Ventures1 shared
Emerson Collective1 shared
Alexandria Venture Investments1 shared
D1 Capital Partners1 shared
Perceptive Advisors1 shared
Last updated: 3 March 2026